A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer
20230237
Phase 1 other active
Quick answer
A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer for Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active